The role of the C-terminal domain in the inhibitory functions of tissue factor pathway inhibitor

被引：17

作者：

Ettelaie, C ^{[1
]}

Adam, JM ^{[1
]}

James, NJ ^{[1
]}

Oke, AO ^{[1
]}

Harrison, JA ^{[1
]}

Bunce, TD ^{[1
]}

Bruckdorfer, KR ^{[1
]}

机构：

[1] UCL Royal Free & Univ Coll, Sch Med, Dept Biochem & Mol Biol, London NW3 2PF, England

来源：

FEBS LETTERS | 1999年 / 463卷 / 03期

基金：

英国惠康基金;

关键词：

tissue factor; tissue factor pathway inhibitor; inhibition; C-terminal; Kunitz; lysine; arginine;

D O I：

10.1016/S0014-5793(99)01663-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Tissue factor pathway inhibitor (TFPI) inhibits the activity of coagulation factors VIIa and Xa through Kunitz domains, thereby inhibiting the activity of tissue factor. However, it has been shown that the C-terminal of this inhibitor is essential for the maximal anticoagulant activity of TFPI, We have investigated the endogenous ability of the C-terminal of TFPI to influence coagulation, A synthetic peptide corresponding to residues 254-265 within the C-terminal of TFPI was prepared and shown to be capable of inhibiting tissue factor pathway by preventing the activation of factor VII, Mutational analysis of the peptide revealed the identity of the key lysine residues. (C) 1999 Federation of European Biochemical Societies.

引用

页码：341 / 344

页数：4

共 24 条

[1]

Modification of tissue factor by peroxynitrite influences its procoagulant activity [J].

Adam, JM ;

Ettelaie, C ;

Naseem, KM ;

James, NJ ;

Bradley, NJ ;

Bruckdorfer, KR .

FEBS LETTERS, 1998, 429 (03) :347-350

[2]

Atherton E, 1989, SOLID PHASE SYNTHESI

[3]

The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor [J].

Banner, DW ;

DArcy, A ;

Chene, C ;

Winkler, FK ;

Guha, A ;

Konigsberg, WH ;

Nemerson, Y ;

Kirchhofer, D .

NATURE, 1996, 380 (6569) :41-46

[4]

Development of a method to separate lipoprotein-bound and lipoprotein-depleted tissue factor pathway inhibitor.: Measurement of free tissue factor pathway inhibitor activity [J].

Bridey, F ;

Lacombe, C ;

Sustendal, L ;

Moatti, D ;

Combe, F ;

Mammès, O ;

de Prost, D .

BLOOD COAGULATION & FIBRINOLYSIS, 1998, 9 (07) :637-643

[5]

BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90

[6]

1-HYDROXY-7-AZABENZOTRIAZOLE - AN EFFICIENT PEPTIDE COUPLING ADDITIVE [J].

CARPINO, LA .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1993, 115 (10) :4397-4398

[7]

Identification of a domain in apolipoprotein B-100 that inhibits the procoagulant activity of tissue factor [J].

Ettelaie, C ;

James, NJ ;

Adam, JM ;

Nicola, KP ;

Wilbourn, BR ;

Bruckdorfer, KR .

BIOCHEMICAL JOURNAL, 1998, 333 :433-438

[8]

Alterations in the structure of apolipoprotein B-100 determine the behaviour of LDL towards thromboplastin [J].

Ettelaie, C ;

Haris, PI ;

James, NJ ;

Wilbourn, B ;

Adam, JM ;

Bruckdorfer, KR .

BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1997, 1345 (03) :237-247

[9]

The mechanism of inhibition of factor III (thromboplastin) activity by apolipoprotein B-100 - Protein-protein interactions [J].

Ettelaie, C ;

James, NJ ;

Wilbourn, B ;

Adam, JM ;

Naseem, KM ;

Bruckdorfer, KR .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (05) :639-647

[10]

Comparison of the inhibitory effects of ApoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation [J].

Ettelaie, C ;

Wilbourn, BR ;

Adam, JM ;

James, NJ ;

Bruckdorfer, KR .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (07) :1784-1790

← 1 2 3 →